Stomatognathic diseases. Pathological conditions, signs and symptoms. Other specified disorders of teeth and supporting structures
Conditions
Interventions
After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (
Drug
Procedure/surgery
E06.892
G02.111.325.500
D02.886.665.500
Sponsors
Faculdade de Odontologia de Bauru
Faculdade de Odontologia de Bauru
Eligibility
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Healthy volunteers of both genders; between 18 and 60 years; are not making use of nonsteroidal anti-inflammatory drugs in the last 7 days.
Exclusion criteria
Exclusion criteria: Local anesthetics allergy, history of gastrointestinal bleeding or ulcers; kidney disease; asthma; allergy or sensitivity to aspirin or any other anti-inflammatory non-steroid agent; pregnant or nursing women; patients using antidepressant; diuretic or aspirin; patients received antibiotics for 30 days prior to surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome: Reduction of consumption of rescue medication associated with piroxicam use in mutated patients for CYP2C9, as assessed by the information contained in the patient's record sheet for the seven-day postoperative period.;Outcome found: Consumption rescue medication associated with the use of piroxicam was the same among patients mutated or not mutated for CYP2C9, evaluated the information contained in the patient's notes sheet as the postoperative period of seven days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected Outcome: Increased reports of adverse effects in patients mutated during the postoperative period until suture removal seven days after extraction of the included and / or impacted third molar, assessed through the information contained in the patient's chart and records.;Outcome found: Absence of severe adverse effects reports for all patients, mutated or not to CYP2C9 during the postoperative period until suture removal seven days after extraction of third molar included and / or impacted, assessed by the information contained in the medical records and records of the patient. | — |
Countries
Brazil
Contacts
Public ContactAdriana;Adriana Calvo;Calvo
Faculdade de Odontologia de Bauru;Faculdade de Odontologia de Bauru
Outcome results
None listed